Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.920.42%
QQQ
717.420.03%
BTC/USD
79444.102.254%
DIA
534.010.54%
GLD
407.570.64%
TLT
82.350.34%

CERO TERAPEUTICS HLDG INC by CERo Therapeutics Holdings, Inc.

CEROOTCQB
Trade with Public
Trade with Public
$0.0107
-0.0844-88.75%
Last update: Sep 4, 11:44 AM
M&A: CERo Therapeutics Hldgs (CERO) sold assets to SRX Global (SRXH) on Monday, August 31, 2026
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompare

CERO TERAPEUTICS HLDG INC by CERo Therapeutics Holdings, Inc. Analyst Price Targets

Wall Street analyst price targets and consensus rating for CERO TERAPEUTICS HLDG INC by CERo Therapeutics Holdings, Inc. (CERO).

Price Target Range — 2 Quarters

Analyst Consensus — 2 Analysts

2Hold
# Analysts2

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Nov 18, 2025D. Boral CapitalJason KolbertDowngradeBuy→Hold—
Nov 3, 2025Maxim GroupJason McCarthyDowngradeBuy→Hold—
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Downgrades CERo Therapeutics Hldgs to Hold

Maxim Group analyst Jason McCarthy downgrades CERo Therapeutics Hldgs (NASDAQ:CERO) from Buy to Hold.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price target.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price target.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price target.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price target.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved